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The British Medical Journal (BMJ) is distributed, at no extra
charge, at weekly intervals to all members of the British
Medical Association. It is therefore the most widely read
journal by doctors with a spectrum of readers varying from
general practitioners to hospital consultants in all specialities.
This book represents a compilation of a series of review
articles published in the BMJ in 1992 whose aim was to
examine the present state of management of a number of
malignancies. It also attempts to increase understanding of
the biology of these diseases, their treatment and their impact
on people. Since the treatment of patients with cancer
requires a broad approach, and usually involves interaction
between many doctors of differing backgrounds, a series of
review articles in a general medical journal is timely. The
level at which such a series of articles should be pitched is
perhaps somewhat more problematic.
The book contains chapters ranging from the common
malignancies of lung, breast and colo-rectum to current
issues in biological therapy, molecular genetics, and quality
of life. It was a pleasure to see a useful contribution relating
to radiotherapy often sadly and inappropriately neglected in
such a book, for a modality of therapy that is utilised in up
to 50% of patients with cancer. Perhaps inevitably, half of
the book is taken up with reviews of unusual but curable
tumours including testicular cancer, Hodgkin's disease and
non-Hodgkin's lymphoma. The thrust of each chapter is not
consistent and tends to reflect the special interests of the
author. In general however, the information provided is well
written, readily understandable and enumerates the current
status of general principles of cancer treatment. There is
appropriate detail of important major developments in com-
mon cancers such as implementation of adjuvant therapy in
high risk patients with rectal and colonic carcinoma, and also
confirmation of the benefit of adjuvant therapy in the man-
agement of early breast cancer derived from a recent meta-
analysis. One notable chapter is by Maurice Slevin regarding
quality of life, implicitly recognised as an important measure
that should be assessed in most cancer trials, particularly
where treatments are given with palliative intent. Currently
palliative therapy is often delayed until the onset of
significant symptoms. Dr Slevin advances the perhaps
unfashionable view that more efficacious, even if substantially
more toxic, palliative treatment given earlier may be of
benefit. I do however take issue with the statement on the
back cover that 'rarer diseases such as Hodgkin's lymphoma
may act as models for research in other cancers'. Such an
approach has been tried over the last 30 years. Surely the fact
that the mortality rates for common malignancies such as
breast cancer have remained stubbornly stable in spite of
improved public education, and the wider more rational
prescribing of adjuvant therapy, should render such state-
ments outmoded. A chapter on cancer treatment in the year
2020 should have stimulated some interesting and useful
debate, as it seems likely that increased understanding of
molecular/cellular biology should lead to a major conceptual
shift in cancer management, as suggested in the chapter on
molecular genetics by Bruce Ponder.
As a whole the book is somewhat diverse, and it is not
entirely clear to me who would wish to buy it. For the
specialist it is too general and no doubt many general practi-
tioners would consider it too specialised! When I first saw
these articles as they appeared in the BMJ I thought they
worked rather well, but as a book I am not so sure.
S. Falk
Cytokine Therapy
Edited by D.W. Galvani & J.C. Cawley, Cambridge Univer-
sity Press, 1992, 193 pp., £35.00 Hardback, £15.00 Paper-
back.
The first biological response modifiers to reach patients were
unlike any anticancer drugs previously tested. Intense public
interest was aroused, but initial enthusiasm was replaced by
crashing disappointment after reports of serious toxicities.
This book seeks to provide a balanced overview of the
cytokines now entering clinical practice.
Nine cytokines are presented in concise chapters: erythro-
poietin, granulocyte-macrophage colony stimulating factor
(GM-CSF), granulocyte colony stimulating factor (G-CSF),
interleukins-1, -2 and -3, interferons alpha and gamma, and
tumour necrosis factor. A final chapter explores the complex-
ities of the cytokine network. An international panel of
contributors, mainly haematologists, describe the molecular
and biological properties of each cytokine before discussing
the clinical trial experience. Their assessments range from
euphoric to sceptical. For example, there is an interesting
contrast in the approaches of Takaku (describing G-CSF)
and Khwaja and Linch (describing GM-CSF). These two
drugs are now being marketed for the same indication, to
reduce the severity of neutropenia and neutropenic sepsis
after cytotoxic chemotherapy. The former expects G-CSF
treatment after chemotherapy 'to become standard therapy
for cancer patients in the very near future' whereas the latter
feel that GM-CSF 'cannot be recommended . . . in associa-
tion with conventional chemotherapy' and 'it is still not clear
whether (its use) is justifiable on a routine basis' after bone
marrow transplantation.
The most successful chapters are those on erythropoietin,
GM-CSF and alpha interferon which are the best charac-
terised cytokines and have an established clinical role. There
are descriptions of their use in renal failure and viral
hepatitis in addition to their applications in cancer treatment.
The chapters on interleukins-1 and -3 and gamma interferon
are well balanced, despite these cytokines being in a relatively
early stage in development and the uncertainty about their
clinical role.
The editors have sought to provide for their clinical col-
leagues an approachable and easily digestible account of
those cytokines presently in clinical use. The chapters
inevitably differ in their palatability, but each is readily con-
sumed at a single sitting. I think it will be read with benefit
by senior clinicians, junior doctors and other ward staff
involved in cytokine therapy. It does not however constitute
a guide to clinical practice. The section on interleukin-2, for
example, fails to describe the life-threatening toxicities such
as capillary leak syndrome that necessitated intensive care of
early patients. Graduate students and research fellows have
been better served by the comprehensive and consistent
'Cytokines in Cancer Treatment' by Franni Balkwill (1989).
In a fast moving field such as cytokine research, any
account will be incomplete. This book provides a sharp
image of the cytokines now registered for treatment and a
snapshot of those currently undergoing clinical evaluation.
P.J. Woll